BDTX vs IOVA
BDTX: Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across multiple cancer types, with a focus on brain-penetrant therapies for lung cancer and glioblastoma. IOVA: Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma through centralized manufacturing and clinical innovation.
Side-by-side fundamentals
| Metric | BDTX | IOVA | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $1.84 | $5.13 | |
| Market cap as of 2026-07-24 | $105M | $2.3B | |
| P/E as of 2026-07-24 | 4.69 | n/a | |
| Net margin as of 2026-07-24 | +31.9% | -123.9% | BDTX higher |
| Gross margin as of 2026-07-24 | n/a | +36.7% | |
| Operating margin as of 2026-07-24 | +17.9% | -127.2% | BDTX higher |
| ROE as of 2026-07-24 | -36.4% | -50.2% | BDTX higher |
| ROA as of 2026-07-24 | -28.8% | -38.8% | BDTX higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.00 | BDTX lower |
| Revenue growth (YoY) as of 2026-07-24 | n/a | +34.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1388.7% | |
| Beta as of 2026-07-24 | 3.23 | 0.66 | |
| 1-year return as of 2026-07-23 close | -42.6% | +29.2% | IOVA higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.